Page 32 - 2018_11-Haematologica-web

Ferrata Storti Foundation
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Haematologica 2018 Volume 103(11):1772-1784
Jo Caers,1,2 Laurent Garderet,3 K. Martin Kortüm,4 Michael E. O’Dwyer,5 Niels W.C.J. van de Donk,6 Mascha Binder,7 Sandra Maria Dold,8 Francesca Gay,9 Jill Corre,10 Yves Beguin,1,2 Heinz Ludwig,11 Alessandra Larocca,9 Christoph Driessen,12 Meletios A. Dimopoulos,13 Mario Boccadoro,9 Martin Gramatzki,14 Sonja Zweegman,6 Hermann Einsele,4 Michele Cavo,15 Hartmut Goldschmidt,16,17 Pieter Sonneveld,18 Michel Delforge,19 Holger W. Auner,20 Evangelos Terpos13 and Monika Engelhardt8
1Department of Hematology, University Hospital of Liege, Belgium; 2Laboratory of Hematology, GIGA-I3, University of Liège, Belgium; 3Department of Hematology, Hopital Saint Antoine, Paris, France; 4Department of Internal Medicine II, University Hospital of Wuerzburg, Germany; 5Department of Hematology, National University of Ireland Galway, Ireland; 6 Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands, 7Department of Internal Medicine II, University Medical Center Hamburg- Eppendorf, Hamburg, Germany; 8Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Germany; 9Department of Hematology-Oncology, University Hospital Città della Salute e della Scienza, Torino, Italy; 10Unit for Genomics in Myeloma, Institut Universitaire du Cancer – Oncopole, Toulouse, France; 11Wilhelminen Cancer Research Institute, Vienna, Austria; 12Department of Oncology and Hematology, Cantonal Hospital St. Gallen, Switzerland; 13School of Medicine, National and Kapodistrian University of Athens, Greece; 14Division of Stem Cell Transplantation and Immunotherapy, University of Kiel, Germany; 15Seragnoli 'Institute of Hematology, Bologna University School of Medicine, Italy; 16Department of Hematology, Rheumatology and Oncology, University Hospital Heidelberg, Germany; 17National Center for Tumor Diseases, Heidelberg Medical University, Germany; 18Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 19Department of Hematology, University Hospital Leuven, Belgium and 20Centre for Haematology, Hammersmith Hospital, Imperial College London, UK
ABSTRACT
The diagnosis of multiple myeloma can be challenging, even for experienced physicians, and requires close collaboration between numerous disciplines (orthopedics, radiology, nuclear medicine, radiation therapy, hematology and oncology) before the final diagnosis of myeloma is made. The definition of multiple myeloma is based on the presence of clinical, biochemical, histopathological, and radiological markers of disease. Specific tests are needed both at presentation and dur- ing follow-up in order to reach the correct diagnosis and characterize the disease precisely. These tests can also serve prognostic purposes and are useful for follow-up of myeloma patients. Molecular analyses remain piv- otal for defining high-risk myeloma and are used in updated patient strat- ifications, while minimal residual disease assessment via flow cytometry, molecular techniques and radiological approaches provides additional prognostic information on patients’ long-term outcome. This pivotal information will guide our future treatment decisions in forthcoming clinical trials. The European Myeloma Network group updated their guidelines on different diagnostic recommendations, which should be of value to enable appropriate use of the recommendations both at diagno- sis and during follow-up.
Correspondence:
jo.caers@chu.ulg.ac.be
Received: January 21, 2018. Accepted: August 27, 2018. Pre-published: August 31, 2018.
doi:10.3324/haematol.2018.189159
Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/103/11/1772
©2018 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
1772
haematologica | 2018; 103(11)
GUIDELINE ARTICLE